Listen "AUA2023: Contemporary Pharmacotherapy for OAB 2023"
Episode Synopsis
AUA2023: Contemporary Pharmacotherapy for OAB 2023
CME Available: https://auau.auanet.org/node/38282
Release Date: May, 2023
Expiration Date: May, 2024
ACKNOWLEDGEMENTS
Independent educational grant support provided by:
Astellas
Urovant Sciences, Inc.
LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
1. Define the similarities and differences between the various oral pharmacotherapies for OAB.
2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta3 agonists and combination therapy.
3. Explain the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.
4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents.
5. Discuss potential future pharmacological pathways and therapies for OAB.
CME Available: https://auau.auanet.org/node/38282
Release Date: May, 2023
Expiration Date: May, 2024
ACKNOWLEDGEMENTS
Independent educational grant support provided by:
Astellas
Urovant Sciences, Inc.
LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
1. Define the similarities and differences between the various oral pharmacotherapies for OAB.
2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta3 agonists and combination therapy.
3. Explain the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.
4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents.
5. Discuss potential future pharmacological pathways and therapies for OAB.
More episodes of the podcast AUAUniversity
Core Curriculum: Anorectal Malformation
22/10/2025
The Latest Breakthroughs in mHSPC
24/09/2025
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.